4-(5-fluoro-1H-benzo[d]imidazol-2-yl)aniline | 872552-44-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-(5-fluoro-1H-benzo[d]imidazol-2-yl)aniline
• 英文别名: 4-(5-fluoro-1H-1,3-benzodiazol-2-yl)aniline；4-(6-fluoro-1H-benzimidazol-2-yl)aniline
• CAS: 872552-44-8
• 化学式: C₁₃H₁₀FN₃
• mdl: MFCD12603544
• 分子量: 227.241
• InChiKey: OHGFHBIPTNBMQE-UHFFFAOYSA-N

物化性质

• 沸点：
  469.0±51.0 °C(Predicted)
• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(5-fluoro-1H-benzo[d]imidazol-2-yl)aniline 在 硫酸 作用下， 以 四氢呋喃 为溶剂， 生成 methyl 5-((4-(5-fluoro-1H-benzo[d]imidazol-2-yl)phenyl)amino)-5-oxopentanoate
  参考文献：
  名称：

  Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus

  摘要：

  The gyraseB subunit of Staphylococcus aureus DNA gyrase is a well-established and validated target though less explored for the development of novel antimicrobial agents. Starting from the available structural information in PDB (3TTZ), we identified a novel series of benzimidazole used as inhibitors of DNA gyraseB with low micromolar inhibitory activity by employing structure-based drug design strategy. Subsequently, this chemical class of DNA gyrase inhibitors was extensively investigated biologically through in vitro assays, biofilm inhibition assays, cytotoxicity, and in vivo studies. The binding affinity of the most potent inhibitor 10 was further ascertained biophysically through differential scanning fluorimetry. Further, the most potent analogues did not show any signs of cardiotoxicity in Zebra fish ether-a-go-go-related gene (zERG), a major breakthrough among the previously reported cardiotoxic gyraseB inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.09.008
• 作为产物：
  描述：

  1-nitrobenzimidazole 以 Na2S.9H2O 为溶剂， 生成 4-(5-fluoro-1H-benzo[d]imidazol-2-yl)aniline
  参考文献：
  名称：

  Benzimidazole analogs as down-regulators of IgE

  摘要：

  这项发明涉及一类二酰基苯并咪唑类似物，它们是抑制对过敏原的IgE反应的抑制剂。这些化合物在过敏和/或哮喘的治疗中很有用，或者在IgE是致病的任何疾病中也很有用。

  公开号：

  US06369091B1

文献信息

• [EN] ARYL-1,3-AZOLE DERIVATIVES AND METHODS FOR INHIBITING HEPARNASE ACTIVITY<br/>[FR] DERIVES D'ARYL-1,3-AZOLE ET PROCEDES PERMETTANT D'INHIBER L'ACTIVITE DE L'HEPARANASE
  申请人：IMCLONE SYSTEMS INC

  公开号：WO2005030206A1

  公开（公告）日：2005-04-07

  The present invention encompasses heparanase inhibitors, particularly to certain 2-substituted heteroaryl-fused and aryl-fused carbazole derivatives that inhibit heparanase, pharmaceutical compositions that contain the compounds, methods for making the compounds, and methods of treating heparanase-dependent diseases and conditions in mammals by administering a therapeutically effective amount of the compounds to the mammals.

  本发明涵盖了抑制肝素酶的抑制剂，特别是特定的2-取代杂芳基融合和芳基融合的咔唑衍生物，这些衍生物抑制肝素酶，包含这些化合物的药物组合物，制备这些化合物的方法，以及通过向哺乳动物施用这些化合物的治疗有效量来治疗依赖肝素酶的疾病和病况的方法。
• Benzimidazole compounds for regulating IgE
  申请人：——

  公开号：US20030100582A1

  公开（公告）日：2003-05-29

  This invention relates to a family of phenylbenzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

  这项发明涉及一类苯基苯并咪唑类似物，它们是抑制对过敏原的IgE反应的抑制剂。这些化合物在治疗过敏和/或哮喘或任何IgE致病的疾病中是有用的。
• Direct Deaminative Functionalization
  作者：Balu D. Dherange、Mingbin Yuan、Christopher B. Kelly、Christopher A. Reiher、Cristina Grosanu、Kathleen J. Berger、Osvaldo Gutierrez、Mark D. Levin

  DOI：10.1021/jacs.2c11453

  日期：2023.1.11

  conversion of amines to bromides, chlorides, iodides, phosphates, thioethers, and alcohols, the heart of which is a deaminative carbon-centered radical formation process using an anomeric amide reagent. Experimental and computational mechanistic studies demonstrate that successful deaminative functionalization relies not only on outcompeting the H-atom transfer to the incipient radical but also on the generation

  复杂分子环境中的选择性官能团相互转化是现代有机合成面临的许多挑战的基础。目前，一个享有特权的功能群体子集在这一领域占据主导地位，而其他功能群体尽管数量众多，但却严重不发达。胺是这种二分法的缩影。它们数量丰富，但在其他方面却坚决不肯直接相互转化。在这里，我们报告了一种能够将胺直接转化为溴化物、氯化物、碘化物、磷酸盐、硫醚和醇的方法，其核心是使用异头酰胺试剂的脱氨基碳中心自由基形成过程。实验和计算机理研究表明，成功的脱氨基功能化不仅依赖于竞争氢原子向初始自由基的转移，而且还依赖于极性匹配、高效的携带链的自由基的生成，这些自由基能够继续有效地反应。通过高通量平行合成评估了该技术对胺库相互转化的总体影响，并将其应用于一锅多样化方案的开发。
• Benzimidazole-2-Phenyl-Carboxamides as Dual-Target Inhibitors of BVDV Entry and Replication
  作者：Roberta Ibba、Federico Riu、Ilenia Delogu、Ilenia Lupinu、Gavino Carboni、Roberta Loddo、Sandra Piras、Antonio Carta

  DOI：10.3390/v14061300

  日期：——

  Bovine viral diarrhea virus (BVDV), also known as Pestivirus A, causes severe infection mostly in cattle, but also in pigs, sheep and goats, causing huge economical losses on agricultural farms every year. The infections are actually controlled by isolation of persistently infected animals and vaccination, but no antivirals are currently available to control the spread of BVDV on farms. BVDV binds the host cell using envelope protein E2, which has only recently been targeted in the research of a potent and efficient antiviral. In contrast, RdRp has been successfully inhibited by several classes of compounds in the last few decades. As a part of an enduring antiviral research agenda, we designed a new series of derivatives that emerged from an isosteric substitution of the main scaffold in previously reported anti-BVDV compounds. Here, the new compounds were characterized and tested, where several turned out to be potent and selectively active against BVDV. The mechanism of action was thoroughly studied using a time-of-drug-addition assay and the results were validated using docking simulations.

  牛病毒性腹泻病毒（BVDV）又称 Pestivirus A，主要引起牛的严重感染，也可引起猪、绵羊和山羊的严重感染，每年给农业农场造成巨大的经济损失。实际上，通过隔离持续感染的动物和接种疫苗可以控制感染，但目前还没有抗病毒药物可以控制 BVDV 在农场的传播。BVDV 利用包膜蛋白 E2 与宿主细胞结合，而这种蛋白直到最近才成为强效抗病毒药物研究的目标。相比之下，RdRp 在过去几十年中已被几类化合物成功抑制。作为持久抗病毒研究议程的一部分，我们设计了一系列新的衍生物，这些衍生物是通过对以前报道过的抗 BVDV 化合物中的主要支架进行同位取代而产生的。在这里，我们对新化合物进行了表征和测试，结果表明其中几种化合物对 BVDV 具有强效和选择性活性。利用加药时间测定法对其作用机制进行了深入研究，并利用对接模拟对结果进行了验证。
• 1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors
  作者：Weitao Pan、Hua-Quan Miao、Yong-Jiang Xu、Elizabeth C. Navarro、James R. Tonra、Erik Corcoran、Armin Lahiji、Paul Kussie、Alexander S. Kiselyov、Wai C. Wong、Hu Liu

  DOI：10.1016/j.bmcl.2005.09.069

  日期：2006.1

  A novel class of 1-[4-(1H-benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-ureas are described as potent inhibitors of heparanase. Among them are 1,3-bis-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea (7a) and 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)-phenyl]-urea (7d), which displayed good heparanase inhibitory activity (IC50 0.075-0.27 mu M). Compound 7a showed good efficacy in a B16 metastasis model. (c) 2005 Elsevier Ltd. All rights reserved.